Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.

@article{Vigan2010LowerIO,
  title={Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.},
  author={Mariagrazia Vigan{\'o} and Thomas Dengler and Marie Françoise Mattei and Ann Poncelet and Johan Vanhaecke and Emmanuelle Vermes and R Kleinloog and Yulan Li and Y Gezahegen and Juan Francisco Delgado},
  journal={Transplant infectious disease : an official journal of the Transplantation Society},
  year={2010},
  volume={12 1},
  pages={23-30}
}
Cytomegalovirus (CMV) is a major cause of infectious complications following cardiac transplantation, severely affecting short- and long-term outcomes. A 12-month, multicenter, randomized, open-label study in de novo cardiac transplant patients was undertaken to compare the efficacy, renal function, and safety of everolimus plus reduced cyclosporine versus mycophenolate mofetil (MMF) plus standard cyclosporine (ClinicalTrials.gov NCT00150046). CMV-specific data was prospectively collected on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

JC.Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.Transplantation

  • AC Webster, LeeVW, Chapman, Craig
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…